Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 5Other solid neoplasm 3Sarcoma 2Head & Neck 2Gynecologic 2Genitourinary 2NET 1Endocrine 1

Conditions

Gastrointestinal Stromal Tumors 2

Interventions

Doxorubicin 44Imatinib Mesylate 33pembrolizumab 23Cyclophosphamide 23Sunitinib 22Gemcitabine 22Temozolomide 17Irinotecan 14Bevacizumab 14Docetaxel 13nilotinib 12Trabectedin 12ripretinib 11pazopanib 11olaratumab 10fludarabine 10eribulin 10regorafenib 9avapritinib 9Fluorouracil 9Carboplatin 9Paclitaxel 8Nivolumab 8Ifosfamide 8Ibandronic Acid 8spartalizumab 7anlotinib 7Vincristine 7Radiation 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × famitinib × Sarcoma × Clear all
NCT04409223 2024-02-09

Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
185 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02336724 2018-04-17

A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
88 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡